Director James C. Foster of Charles River Laboratories International, Inc. filed a Form 4 on October 23, 2026, reporting the exercise of stock options and sale of 24,042 shares of common stock on October 22, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Foster acquired 24,042 shares of common stock on October 22, 2026, via a stock option exercise (transaction code M) at an exercise price of $244.41 per share.
  • Sale of shares: Foster disposed of 24,042 shares on October 22, 2026, at a price of $350 per share (transaction code S).
  • 10b5-1 plan: According to the filing, the transaction was made pursuant to a Rule 10b5-1 trading plan initially adopted on March 6, 2026.
  • Direct beneficial ownership following transactions: Foster directly holds 31,596 shares of common stock following the reported transactions.
  • Indirect holdings: Foster also holds shares indirectly, including 5,423 shares via a 2024 GRAT, 10,780 via a 2025 GRAT, 20,000 via a 2026 GRAT, 10,000 by a trust held by spouse, and 155,611 by trust.
  • Options fully exercised: The stock options exercised, with an expiration date of May 27, 2032, were fully consumed, leaving zero options of that grant remaining.

Foster Option Exercise and Planned Sale Details at Charles River Laboratories

According to the Form 4 filed with the SEC, James C. Foster, identified as a Director of Charles River Laboratories International, Inc. (NYSE:CRL), reported two transactions in the company's common stock on October 22, 2026. First, Foster exercised stock options to acquire 24,042 shares at a conversion price of $244.41 per share (transaction code M). The underlying options carried an expiration date of May 27, 2032, and a date exercisable of May 27, 2023. Following the exercise, all 24,042 derivative securities from that grant were reported as no longer held.

On the same date, Foster disposed of 24,042 shares at a price of $350 per share (transaction code S). The filing states that "this exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026." The form was signed by Kerry Dailey as attorney-in-fact for James C. Foster, and is dated October 23, 2026.

Following these transactions, Foster directly held 31,596 shares of common stock. In addition, the filing discloses indirect beneficial ownership positions: 5,423 shares through a 2024 GRAT, 10,780 shares through a 2025 GRAT, 20,000 shares through a 2026 GRAT, 10,000 shares through a trust held by his spouse, and 155,611 shares through a separate trust. The filing also notes that the form was filed with the "Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan" box checked.

What Was Disclosed

The filing discloses a Director-level Form 4 reporting an option exercise of 24,042 Charles River Laboratories shares at $244.41 and a same-day sale of 24,042 shares at $350, conducted under a Rule 10b5-1 plan adopted March 6, 2026, with resulting direct ownership of 31,596 shares.